A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)

Trial Profile

A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms EVIDENCE
  • Sponsors Roche
  • Most Recent Events

    • 16 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 29 Jan 2018 Planned End Date changed from 21 Nov 2017 to 28 Feb 2018.
    • 29 Jan 2018 Planned primary completion date changed from 21 Nov 2017 to 28 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top